Vaxart, Inc. (VXRT)
0.6274
-0.05
(-7.73%)
USD |
OTCM |
May 18, 15:59
Vaxart Research and Development Expense (Quarterly) : 29.41M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 13.75M |
| Capricor Therapeutics, Inc. | 27.10M |
| Allogene Therapeutics, Inc. | 29.13M |
| Agenus, Inc. | 11.82M |
| Curis, Inc. | 6.449M |